2112 results about "Vitamin a1" patented technology

The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel. In addition to calcium, the transdermal pharmaceutical composition may also contain a therapeutically effective amount of: (1) a pharmaceutically acceptably salt of other minerals such as magnesium, zinc, selenium, manganese, or chromium; (2) a vitamin such as vitamin A, vitamin D, vitamin C, vitamin E or B-complex vitamins, choline, lecithin, inositol, PABA, biotin, or bioflavomoids; (3) a carotenoid such as lycopene or lutein; (4) a hormone such as dehydroepiandrosterone, progesterone, pregnenolone, or melatonin; (5) an amino acid such as arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, or acetyl-l-carnitine; (6) a fatty acid such as a fish oil or flax seed oil; (7) a vita-nutrient such as coenzyme Q10; (8) a cartilage building nutrient such as glucosamine, chondroitin, or MSM, (9) a herb such as ginkgo biloba, echinacea, 5-HTP, St. John's wort, or saw palmetto; or (9) any combination thereof. The transdermal pharmaceutical composition may be topically administered to a human to prevent or reduce the likelihood of calcium deficiency or imbalances caused by calcium deficiency such as hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.

A dietary supplement of mitochondrial nutrients is designed for relieving stress, preventing and improving stress-related disorders, such as chronic fatigue syndrome, diabetes, age-associated cognitive dysfunction and diseases (Parkinson's and Alzheimer's disease). The supplement composition has the following nutrients: B vitamins (cyanocobalamin 2-1,000 ug, thiamin 1-1,000 mg, niacin 15-2,000 mg, pyridoxine 1-1,000 mg, Pantothenate 5-150 mg, folic acid 400-40,000 ug), alpha-tocopherol 10-800 mg, ascorbic acid 50-10,000 mg, calcium 20-2,000 mg, vitamin A 200-10,000 ug, alpha-lipoic acid 100-1,000 mg, N-acetyl cysteine 100-3,000 mg, L-carnosine 100-9,000 mg, tyrosine 100-9,000 mg, vanillin 10-100 mg, phosphatidylserine 10-800 mg, resveratrol 10-50 mg, dehydroepiandrosterone 1-50 mg, and melatonin 0.1-3 mg, all of which have been individually used experimentally or clinically for relieving stress, preventing and treating age- and stress-related disorders and diseases but no combination of these compounds has been used. Many embodiments also contain at least one adjunct ingredient such as coenzyme Q 10-200 mg, acetyl-L-carnitine 100-2,000 mg, choline 50-1,000 mg, and creatine 100-2,000 mg.

A nutritional supplement composition that promotes visual health and reduces or reverses visual acuity loss by a reduced Vitamin E content from standard supplements with the addition of taurine, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and zeaxanthin. The essential ingredients of the nutritional or dietary supplements are Vitamin C, no more than 300 IUs of Vitamin E, Vitamin A at least a portion of which is provided in the form of a proform Vitamin A carotenoid, omega-3 fatty acids, and non proform Vitamin A carotenoids including lutein and / or zeaxanthin. The essential ingredients are provided in a form suitable of oral ingestion or other forms of administration in one or more doses per day.

An astrocyte-specific drug carrier containing a retinoid derivative and / or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for treating complications associated with pulmonary disease such as corticosteroid resistance and pulmonary tissue destruction. The compositions of the present disclosure comprise corticosteroid resistance agents including but not limited to vitamin D, calcitriol and equivalents thereof. The compositions of the present disclosure also comprise alveolar development and maintenance agents including but not limited to vitamin A, ATRA and equivalents thereof. The present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.

Disclosed is an ophthalmic composition containing (A) not less than 50,000 units / 100 mL of vitamin A, (B) not less than 0.4 W / V % of a polyoxyethylene polyoxypropylene glycol, and (C) trometamol.

The present invention relates to compositions, kits and methods for the administration of various vitamin, mineral and nutrient compositions, and in a specific embodiment, the compositions, kits and methods may utilize or include vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega 3 fatty acids and one or more pharmaceutically acceptable carriers.

A resistant to body fluids, organic oil-based topical transdermal composition for the alleviation and treatment of infant skin conditions, including, dry, sensitive, chapped, cracked, itching reddened, and flaking skin, as well as infant skin infirmities associated with eczema, dermatitis, and diaper rash, which has as main constituents, organic oil lipids, vitamin A, tocopheral linoleate, and tincture of benzoin, in an organic beeswax emulsifying base.

A method for administering an antioxidant composition to humans according to their age and sex is disclosed wherein the method comprises administering to said humans a daily dose of a multiple antioxidant micronutrient composition comprising vitamin A (palmitate), beta carotene (from natural d. salina), vitamin C (calcium ascorbate), vitamin D-3 (cholecalciferol), natural source vitamin E including both d-alpha tocopheryl and d-alpha tocopheryl acid succinate, thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid (folacin), d-biotin, selenium (1-seleno methionine), chromium picolinate, zinc glycinate, calcium citrate, and magnesium citrate. For persons over the age of about 51, the composition preferably further comprises one or more of co-enzyme Q10, N-acetyl cysteine, and alpha lipoic acid. Preferably, also, vitamin D is added for women over the age of about 36.

An astrocyte-specific drug carrier containing a retinoid derivative and / or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

A dietary nutritional supplement is designed specifically to address the needs of moderate to heavy alcohol product consumers. The nutritional supplement contains effective amounts of essential components vitamin B2, vitamin B6, vitamin B12 (Cobalamin), vitamin B3 (Niacin), vitamin B1 (Thiamin), Calcium, magnesium, vitamin A, vitamin C (ascorbic acid), folic acid, L-cysteine, L-methionine, Milk Thistle, selenium, dandelion, and Molybdenum.

The invention provides a nano nutrient microemulsion and a preparation method thereof. The nano nutrient microemulsion comprises active components, auxiliary materials and a solvent, wherein the active components comprise vitamins and amino acid, and the auxiliary materials comprise an emulsifier and an assistant emulsifier. According to parts by weight, the active components particularly comprise 5-50 parts of vitamin A, 1-10 parts of vitamin D3, 1-10 parts of vitamin E, 1-5 parts of vitamin B1, 1-5 parts of vitamin B 6, 0.01-0.5 part of vitamin B12, 1-10 parts of vitamin C, 1-10 parts of vitamin K, 1-10 parts of D-calcium pantothenate, 0.5-5.0 parts of L-lysine, 0.5-5.0 parts of DL-methionine and 0.5-5.0 parts of L-arginine. The invention further provides the preparation method for the nano nutrient microemulsion, which prepares the oil-in-water microemulsion by uniformly mixing an oil phase with an aqueous phase. With stable thermodynamic property, high bioavailability, simple preparation method and easy operation, the nano nutrient microemulsion can be widely used in such industries as feed, cosmetics, medicine, beverages, health care products and the like.

Methods and pharmaceutical compositions for use in the treatment of a benign and / or a malignant proliferative pathologies are disclosed. The methods comprise administration of nicotinamide or its analogs and / or cADPR or its analogs, optionally in combination with a vitamin D3 analog or a Vitamin A analog.

The invention discloses a pet dog food composition which comprises the raw materials based on parts by weight: 20-30 parts of corn, 10-20 parts of rice, 10-20 parts of soybean meal, 5-20 parts of chicken powder, 0.3-1 part of salt, 1-2 parts of chicken liver powder, 0.3-1 part of core material, 10-15 parts of milk powder, 1-10 parts of apple pulp and 5-15 parts of chicken grease; wherein the core material is formed by the raw materials based on parts by weight: 1 part of vitamin A, 0.1 part of vitamin D3, 2 parts of vitamin E, 2 parts of vitamin C fat, 0.1part of vitamin B1, 0.2 part of vitamin B2, 0.7 part of nicotinamide, 0.1 part of folic acid, 50 parts of choline, 10 parts of ferrum, 1 part of copper, 10 parts of zinc, 0.3 part of 1% iodine, 0.2 part of tea polyphenol, 100 parts of methionine, 215 parts of yeast powder, 500 parts of deep sea fish oil and 207.3 parts of carrier. The pet dog food has comprehensive and balanced nutrition as well as scientific and reasonable collocation, effectively improves the immunity of pet dogs, promotes growth and development of the dogs and protects the digestive tract to be healthy.

The present invention provides improved dietary supplements and methods for inhibiting the progression of macular degeneration and promoting healthy vision, while at the same time maintaining general health. The dietary supplements of the invention contain vitamin E and carotenoids in the form of Vitamin A, lutein and / or zeaxanthine. The dietary supplements of the invention further contain Vitamin C, copper and zinc and may also contain such ingredients as rosemary, DHA, and other vitamins and minerals.

The invention discloses a skin care agent capable of removing freckles, whitening, preventing wrinkles, moisturizing and resisting allergy and ageing, and a preparation method of the skin care agent. The skin care agent is characterized by comprising the following raw materials in parts by weight: 0.1-10 parts of an aloe extract, 0.1-5 parts of vitamin A, 0.1-10 parts of vitamin D, 0.1-0.5 part of hyaluronic acid, 0.1-5 parts of a swertia mileensis extract, 0.1-2 parts of alpha-lipoic acid, 0.1-5 parts of a licorice extract, 0.1-3 parts of a green tea extract, 0.1-2 parts of a fructus viticis extract and 0.1-3 parts of a grape seed extract. The preparation method comprises the following steps of: respectively adding the substances into deionized water at 75-85 DEG C, and maintaining the constant temperature for 20min; cooling the water to 50 DEG C, and adding 1-2 parts of Twain-200 into the cooled product; and stirring and cooling the solution to obtain the skin care agent. The skin care agent has the beneficial effects of being reasonably prepared from the natural extracts, being capable of permeating into a corium layer so as to accelerate metabolism, repair damaged skin and recover and maintain the elasticity of the skin, and being capable of rapidly achieving the special effects of removing freckles, whitening, preventing wrinkles, moisturizing and resisting allergy and ageing.

The invention provides a feed additive for improving the quality of the fur of a furry animal. The additive is obtained by mixing a semi-finished vitamin product, a semi-finished trace element product, dihydropyridine, methionine, cystine and corn gluten meal according to a weight ratio of 1:1:0.3-1:0.2-0.9:0.1-0.6:2, wherein the semi-finished vitamin product is prepared by uniformly mixing the following components: 5-22 parts of vitamin A, 3-8 parts of vitamin D, 10-25 parts of vitamin E, 3-8 parts of vitamin B1, 8-15 parts of biotin, 1-3 parts of vitamin B6, and 120-160 parts of the corn gluten meal, and the semi-finished trace element product is prepared by uniformly mixing the following components: 10-20 parts of methionine chelated zinc, 2-5 parts of methionine chelated copper, and 70-90 parts of zeolite powder. The additive of the invention allows the quality of the fur of the furry animals (martens, foxes and raccoon dogs) to be substantially improved, the hair density to be increased, the hair length to be improved, the hide toughness to be increased and the culture benefit to be improved.

The present invention relates to compositions comprising DHA, EPA, LA and GLA. The compositions may further comprise other omega-3 PUFAs, MUFAs, SFAs, gamma tocopherol, Vitamin A and Vitamin B. The compositions are useful for treating neurologic disorders. The compositions are administered chronically for the prevention and / or treatment of multiple sclerosis (MS) and other degenerative diseases.

A mineral-fortification system that has a bottle cap, a pouch and a pouch opener. A powder is contained within the pouch, and the powder contains at least one mineral and a redox modulating compound. When the cap is secured onto the opening of a bottle containing a liquid and when the pouch opener is activated, the powder is released from the pouch and mixes with the liquid to form a mineral fortified liquid composition that is fortified with at least one mineral and has a pH between about 2.5 and 9.5. Moreover, the mineral fortified liquid composition has a redox potential that satisfies the following equation:0≧RP−(A−B*pH).In this equation RP is the redox potential in millivolts of the mineral-containing liquid composition, pH is the pH of the mineral-containing liquid composition, A is 400 and B is 20. The mineral is preferably selected from calcium, iron, zinc, copper, manganese, iodine, magnesium, and mixtures of these. Moreover, the mineral-fortified liquid composition may preferably be substantially free of flavor or sweetener compounds. Even more preferably, the liquid composition has no metallic taste or after-taste, a Hunter colorimetric “b” reading of less than 5.0, and an NTU turbidity value of less than 5.0. The mineral-fortified liquid composition may optionally contain other nutrients and vitamins, for example, vitamin A, vitamin C, vitamin E, niacin, thiamin, vitamin B6, vitamin B2, vitamin B 12, folic acid, selenium, pantathonic acid, and iodine.

The invention discloses a lutein ester health care product for protecting eyesight. The lutein ester health care product is prepared by taking lutein ester as a main material, and adding any one or more materials including taurine, selenium, zinc, alpha-lipoic acid, docosahexaenoic acid (DHA), vitamin A, vitamin E, vitamin B1, vitamin B2 and bilberry extract, and pharmaceutically acceptable formulation accessories. The outstanding innovation of the invention is the implementation of the method for preparing a functional eye health care product with the lutein ester instead of lutein, so that the bioavailability, the stability and the health care effect of the product are improved, and production cost can be greatly reduced. The health care product can be prepared into common dosage forms, such as tablets, capsula, granules and soft capsules. The lutein ester health care product is mainly used for the treatment on diseases, such as myopia, amblyopia, hyperopia, presbyopia, cataract, vitreous opacity, retinal pigment degeneration, macular degeneration, asthenopia, and retinopathy caused by diabetes, and the like. The lutein ester health care product adopts a unique formulation of multiple constituents, measures and mechanisms, and has significant treatment effects and excellent social and economic benefits.

The invention provides health-care food for beautifying and brightening hair of a dog, belonging to the field of animal health-care products. The health-care food formula comprises the following components by weight based on 1kg: 10-30g of deep sea fish oil, 10-30g of linseed oil, 5-20g of poppyseed oil, 10-30g of perilla oil, 10-30g of grape seed oil, 10-30g of lecithin, 5-20g of chelate iron, 1-10g of chelate manganese, 5-20g of chelate zinc, 1-5g of chelate copper, 0.05-0.2g of yeast selenium, 150-250g of methionine, 50-150g of lysine, 1-4g of vitamin E, 0.05-0.2g of vitamin D, 0.5-2g of vitamin A, 0.05-0.2g of vitamin B1, 0.1-0.4g of vitamin B2, 0.05-0.2g of vitamin B6, 0.05-0.4g of vitamin B12, 0.05-0.2g of biotin, 0.1-0.4g of nicotinic acid, 1-5g of bacillus, 1-5g of yeast, 120-180gof chicken liver powder, 50-80g of Rosmarinus officinalis and the balance of yeast powder. The components are made into a tablet with the specification of 0.7-0.9g according to a regular tabletting process, and the water content is less than 10%. The health-care food provided by the invention has the advantages of high titer and strong stability and is capable of improving the fur health of the dog, protecting hair follicles and hair shafts against damage, enabling the hair to be smooth and soft, reducing hair slip, promoting regeneration of furs, improving immunity comprehensively and ensuring the dog in a healthy and vital state.

The invention relates to a microbe vitamin premix material and a method for preparing the same, in particular to a microbe vitamin premix material consisting of a plurality of useful microbes and vitamins and a method for preparing the same. The microbe vitamin premix material comprises bacillus, microzyme, enterococcus, vitamin A, vitamin D3, vitamin E, vitamin K3 and vitamin 12, and is the microbe vitamin premix material generally for pigs, poultries, ruminant or aquatic animals. The microbe vitamin premix material has the animal immunization health care function as well as nutrient efficacy, and can improve illness resistant capability of animals, reduce the consumption of antibacterial drugs in feed, lower the drug resistant degree of bacteria, improve the feed utilization ratio, promote health of mankind and improve the ecological environment.

The present invention relates to improving, at least in part, a deficiency in dark adaptation for an individual. The therapy for dark adaptation includes local administration of a retinoid, such as a Vitamin A or a derivative thereof, such that deleterious side effects seen with systemic administration are avoided.

This invention relates to an improved Lyophilized platelet rich plasma used to make a platelet gel wound healant, and methods of preparation and use thereof for healing wounds are disclosed. The improved wound healant comprises therapeutically effective amounts of activated growth factors, platelet ghost, plasma (know as the plasma back bone), white blood cells with optional none, one or more additional anti-oxidant such as vitamin A and / or C and / or E, and / or none one or more antibiotics and / or GHK-Cu (produced by ProCyte Inc.)

The invention provides a method for preparing an intermediate of vitamin A, namely C14-aldehyde, and an intermediate of the C14-aldehyde, namely C14 enol ether, which comprises the following steps of: (1) under the protection of inert gas, performing rearrangement dissociation reaction on C4 phosphonate at the temperature of between -40 and 30DEG C in the presence of alkali in an ether solvent ora dipolar aprotic solvent; (2) adding beta-cyclocitral, and performing Wittig-Homer condensation reaction at the temperature of between -40 and 30DEG C in the presence of alkali in the ether solvent or the dipolar aprotic solvent to obtain the C14 enol ether; and (3) under the protection of inert gas, mixing the C14 enol ether, an acid catalyst, water and a homogenous phase solvent, and performing hydrolysis reaction at the temperature of between 10 and 35DEG C with stirring to obtain the C14-aldehyde. The method has the advantages of simple process, readily available raw materials and low cost, and has great industrial value.

The invention discloses a content analysis and detection method of twelve compound vitamins for injection. Liposoluble components including vitamin A palmitate, vitamin D3 and racemic alpha-tocopherol are detected under the same high-performance liquid phase method conditions, a test solution is prepared by extracting a preparation content by non-polar organic solvent, and the detection wavelength is 265+ / -3nm. Water-soluble components including cocarboxylase tetrahydrate, riboflavin sodium phosphate, vitamin B6, vitamin C, nicotinamide, folic acid and dexpanthenol are detected under the same high-performance liquid phase method conditions, and the detection wavelength is 210+ / -3nm. Biotin and vitamin B12 are subjected to high-performance liquid phase method based detection, the detection wavelength is 200-600nm, and the preferable detection wavelength for the vitamin B12 is 550+ / -3nm. The method has high applicability.

A preparation method of vitamin A and vitamin E nano-sphere / microsphere double-embedding system belongs to the technical field of biological active substance control release microencapsulation. In the present invention, food grade vitamin A is nano-sphere core material and monoglyceride or beeswax is nano-sphere wall material to be made into nano-sphere suspension which is used as microsphere core material together with the vitamin E; ocentyl succinate esterified starch containing tween-80 is used as microsphere wall material; the nano-sphere / microsphere double-embedding system is manufactured by a thermal homogenization-spray drying method. The encapsulation rate towards the vitamin A of vitamin A nano-sphere manufactured by the present invention can reach to 82 percent to 94 percent, and the particle size of the nano-sphere is 200nm to 370nm. The encapsulation rate towards the vitamin A of the double-embedding system is 86 percent to 91 percent and the encapsulation rate towards the vitamin E is 89 percent to 93 percent. The double-embedding system can embed the vitamin A and the vitamin E synchronously and has the effect of releasing step be step, so as to avoid the mutual interference of active components, improve the biological utilization rate and can be added into various foods as vitamin intensifier and extender.

The invention discloses formula milk powder assisting development of height of children. The formula milk powder consists of the following components of raw milk or whole milk powder, desalinated wheypowder, skimmed milk powder, solid corn syrup ( or maltodextrin ), whey protein powder, crystallized fructose, vegetable oil, fructo-oligosaccharide, anhydrous butter, galactooligosaccharide, docosa-hexaenoic, bovine coloctrum powder, milk mineral salt, hydrolyzed dried egg yolk, lactoferrin, phosphatide, vitamin A, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12,vitamin C, magnesium, calcium, iron, zinc, selenium and the like. According to the formula milk powder assisting the development of the height of the children and a production method disclosed by theinvention, the products have the characteristics of ''supplementing, promoting and improving'', namely supplementing nutrition required by growth and development of Chinese children, promoting absorption of key nutrition for the development of the height, and improving immunity of the children, so that the height of the Chinese children is assisted to quickly grow.

This invention is directed to a multi-vitamin and mineral supplement tailored to men and post-menopausal women, pre-menopausal women, and athletes which supplies the right amount of the right micronutrients at the right time to assure adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to lifestyle factors and common inadequate dietary patterns. The multi-vitamin and mineral supplement is comprised of vitamin A, vitamin C, vitamin D, vitamin E, vitamin K, vitamin B1, vitamin B2, niacinamide, vitamin B6, vitamin B12, biotin, pantothenic acid, iron, iodine, magnesium, zinc, selenium, copper, chromium, potassium, choline, lycopene, and co-enzyme Q-10.

The invention discloses an eye medicine combination, containing 200-400 parts by weight of lutein, 1-2 parts by weight of DHA, 6-7 parts by weight of vitamin A and 1.5-2.5 parts by weight of selenium. The components of the eye medicine combination provided by the invention have synergic effect, thus being capable of alleviating symptoms such as asthenopia and dry eye syndrome and being capable of racially controlling and preventing eye problems such as cataract, glaucoma, floaters, macular pigment cytopathy and the like as well, thereby improving eyesight.